The Women's Health Initiative (WHI) study in 2002 created decades of confusion and fear around hormone replacement therapy. Since then, extensive re-analysis and new research have substantially rehabilitated the evidence — particularly for bioidentical hormone therapy initiated within 10 years of menopause or before age 60 (the "timing hypothesis"). The cardiovascular and breast cancer risks highlighted in WHI were primarily in older women using synthetic progestins — not the picture for appropriately timed bioidentical programs.
Current evidence from the British Menopause Society, the Menopause Society, and the European Menopause and Andropause Society supports hormone therapy as a first-line treatment for vasomotor symptoms in appropriate candidates — and notes potential cardiovascular, bone, and cognitive protective effects when initiated during the early menopausal transition.
IV nutritional support plays an important complementary role during hormonal transitions: B vitamins support neurotransmitter synthesis and energy metabolism; magnesium reduces vasomotor symptoms and improves sleep; glutathione addresses the oxidative stress that accelerates during the menopausal transition; and hydration IV sessions address the fatigue and cognitive symptoms that compound while hormonal optimization takes effect.
